Table 4: Adverse events associated with the commercially available TKIs used in thyroid cancer.

Adverse eventSorafenib (%)Sunitinib (%)Pazopanib (%)
All grade≥grade 3All grade≥grade 3All grade≥grade 3

Hypertension1743012404
CHF or LVEF decline1.7NR133<1%NR
ProteinuriaNRNRNRNR9<1
Hand-foot skin reaction3062966NR
StomatitisNRNR3014NR
Anorexia16<1342222
Weight loss10<112<1523.5
Diarrhea432619523.5
AST elevationNRNR562537.5
ALT elevationNRNR512.55312
Fatigue3755411192
HypothyroidismNRNR1427NR
Arterial thromboembolism2.9NRNRNR32
Hemorrhage/bleeding (all sites)153303132

CHF: congestive heart failure; LVEF: left ventricular ejection fraction; AST: aspartate aminotransferase; ALT: alanine aminotransferase; NR: not reported. table adapted from [115].